Revisiting Rose: Strategies for Reducing Coronary Heart Disease

Overview

Journal BMJ

Specialty General Medicine

Date 2006 Mar 18

PMID 16543339

Citations 55

Authors

Douglas G Manuel

Jenny Lim

Peter Tanuseputro

Geoffrey M Anderson

David A Alter

Andreas Laupacis

Cameron A Mustard

Affiliations

Soon will be listed here.

Citing Articles

Population-wide impact of a pragmatic program to identify and manage individuals at high-risk of cardiovascular disease: a cluster randomized trial in 120 villages from Northern China.

Chen S, Yan L, Feng X, Zhang J, Zhang Y, Zhang R Front Cardiovasc Med. 2024; 11:1372298.

PMID: 38854653 PMC: 11157055. DOI: 10.3389/fcvm.2024.1372298.

Use of Smart Devices to Track Cardiovascular Health Goals in the United States.

Aminorroaya A, Dhingra L, Nargesi A, Oikonomou E, Krumholz H, Khera R JACC Adv. 2023; 2(7).

PMID: 38094515 PMC: 10718569. DOI: 10.1016/j.jacadv.2023.100544.

Burden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019.

Aminorroaya A, Moghaddam S, Tavolinejad H, Aryan Z, Heidari B, Ebrahimi H J Am Heart Assoc. 2023; 13(2):e030165.

PMID: 37956220 PMC: 10926818. DOI: 10.1161/JAHA.123.030165.

Risk of incident cardiovascular diseases at national and subnational levels in Iran from 2000 to 2016 and projection through 2030: Insights from Iran STEPS surveys.

Ebrahimi H, Masinaei M, Aminorroaya A, Aryan Z, Mehdipour P, Rostam-Abadi Y PLoS One. 2023; 18(8):e0290006.

PMID: 37611004 PMC: 10446220. DOI: 10.1371/journal.pone.0290006.

Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk.

Cai X, Xiang Y, Chen X, Lin X, Lin B, Zhou G Cardiovasc Diabetol. 2023; 22(1):198.

PMID: 37537553 PMC: 10398968. DOI: 10.1186/s12933-023-01924-2.

References

Shea S, Basch C . A review of five major community-based cardiovascular disease prevention programs. Part II: Intervention strategies, evaluation methods, and results. Am J Health Promot. 1990; 4(4):279-87. DOI: 10.4278/0890-1171-4.4.279. View

Mantel-Teeuwisse A, Goettsch W, Klungel O, de Boer A, Herings R . Long term persistence with statin treatment in daily medical practice. Heart. 2004; 90(9):1065-6. PMC: 1768444. DOI: 10.1136/hrt.2003.026187. View

Vartiainen E, Heath G, Ford E . Assessing population-based programs to reduce blood cholesterol level and saturated fats. Int J Technol Assess Health Care. 1991; 7(3):315-26. DOI: 10.1017/s0266462300005699. View

Maclean D, Petrasovits A, Nargundkar M, Connelly P, MacLeod E, Edwards A . Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. CMAJ. 1992; 146(11):1969-74. PMC: 1490359. View

Liao Y, McGee D, Cooper R, Sutkowski M . How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999; 137(5):837-45. DOI: 10.1016/s0002-8703(99)70407-2. View

Anderson K, Wilson P, Odell P, Kannel W . An updated coronary risk profile. A statement for health professionals. Circulation. 1991; 83(1):356-62. DOI: 10.1161/01.cir.83.1.356. View

Heidenreich P . Patient adherence: the next frontier in quality improvement. Am J Med. 2004; 117(2):130-2. DOI: 10.1016/j.amjmed.2004.03.007. View

Emberson J, Whincup P, Morris R, Walker M, Ebrahim S . Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004; 25(6):484-91. DOI: 10.1016/j.ehj.2003.11.012. View

Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H . Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000; 355(9205):675-87. DOI: 10.1016/s0140-6736(99)11180-2. View

10.

Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K . Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet. 2000; 355(9205):688-700. DOI: 10.1016/s0140-6736(99)11181-4. View

11.

Rose G . Sick individuals and sick populations. 1985. Bull World Health Organ. 2001; 79(10):990-6. PMC: 2566665. View

12.

. Lipid management guidelines--2001. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. Med J Aust. 2002; 175(S2):S62-85. View

13.

Jackevicius C, Mamdani M, Tu J . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288(4):462-7. DOI: 10.1001/jama.288.4.462. View

14.

Wald N, Law M . A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404):1419. PMC: 162259. DOI: 10.1136/bmj.326.7404.1419. View

15.

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J . European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24(17):1601-10. DOI: 10.1016/s0195-668x(03)00347-6. View

16.

Genest J, Frohlich J, Fodor G, McPherson R . Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003; 169(9):921-4. PMC: 219626. View

17.

Jackevicius C, Tu K, Filate W, Brien S, Tu J . Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol. 2003; 19(12):1359-66. View